Formulation Development and Evaluation of Proniosomal Powder of Candesartan

Bomma, Ganapathi; Harika, S; Babu, Ananthula Madhu; Bakshi, Vasudha

doi:10.1080/22297928.2017.1335612

Cited by 3 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proniosomal formulations exhibited differences in the XRD analysis, as shown in Figure 3; FN1 and FN3 show a high peak, however these peaks are not the significant diffraction peaks of aceclofenac, while maltodextrin gave a board curve. These findings support the hypothesis that proniosome formulations have the ability to decrease the degree of crystallinity of the pure drug and enhance its amorphous nature [33].…”

Section: Resultssupporting

confidence: 86%

Optimization of Aceclofenac Proniosomes by Using Different Carriers, Part 1: Development and Characterization

et al. 2019

View full text Add to dashboard Cite

In the contemporary medical model world, the proniosomal system has been serving as a new drug delivery system that is considered to significantly enhance the bioavailability of drugs with low water solubility. The application of this system can improve the bioavailability of aceclofenac that is used for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The present study is intended to develop an optimized proniosomal aceclofenac formula by the use of different carriers. Aceclofenac proniosomes have been prepared by slurry method, and different carriers such as maltodextrin, mannitol, and glucose were tried. Prepared proniosomes characterized by differential scanning calorimetry (DSC) analysis and Fourier transform infrared (FTIR) analysis revealed the compatibility of the drug chosen with the ingredient added, powder X-ray diffractometry (XRD) confirmed the amorphous phase of the prepared proniosomes, and finally, the surfactant layer was observed by scanning electron microscopy (SEM). Aceclofenac physical state transformations were confirmed with all formulas but maltodextrin proniosomes exhibited solubility more than other formulations. HPLC method has been used to analyze the niosomes derived from proniosomes in terms of their entrapment capability and drug content. The obtained results revealed that aceclofenac proniosomes can be successfully prepared by using different carriers.

show abstract

Section: Resultssupporting

confidence: 86%

Optimization of Aceclofenac Proniosomes by Using Different Carriers, Part 1: Development and Characterization

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The absorbance was measured by a UV-Visible spectrophotometer (3200, LABINDIA, Thane, India) at 305 nm. The % cumulative drug release was calculated using Microsoft Excel and plotted the graph between % cumulative drug release and time [26].…”

Section: In-vitro Release Of Ezlmentioning

confidence: 99%

“…Bomma formulated candesartan loaded PNs using maltodextrin. It exhibited high EE (83.24%) and significant-high release (90.1%) compared to pure candesartan [26]. Maltodextrin is used as the inner material for converting the PNs into PNs powder.…”

Section: Introductionmentioning

confidence: 99%

Development, In-Vitro Characterization and Preclinical Evaluation of Esomeprazole-Encapsulated Proniosomal Formulation for the Enhancement of Anti-Ulcer Activity

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objective: The present study aimed to develop and optimize esomeprazole loaded proniosomes (EZL-PNs) to improve bioavailability and therapeutic efficacy. Method: EZL-PNs formulation was developed by slurry method and optimized by 33 box-Bhekhen statistical design software. Span 60 (surfactant), cholesterol, EZL concentration were taken as independent variables and their effects were evaluated on vesicle size (nm), entrapment efficiency (%, EE) and drug release (%, DR). Furthermore, optimized EZL-PNs (EZL-PNs-opt) formulation was evaluated for ex vivo permeation, pharmacokinetic and ulcer protection activity. Result: The EZL-PNs-opt formulation showed 616 ± 13.21 nm of vesicle size, and 81.21 ± 2.35% of EE. EZL-PNs-opt exhibited negative zeta potential and spherical confirmed scanning electron microscopy. EZL-PNs-opt showed sustained release of EZL (95.07 ± 2.10% in 12 h) than pure EZL dispersion. The ex-vivo gut permeation result exhibited a significantly (p < 0.05) enhanced flux than pure EZL. The in vivo results revealed 4.02-fold enhancement in bioavailability and 61.65% protection in ulcer than pure EZL dispersion (43.82%). Conclusion: Our findings revealed that EZL-PNs formulation could be an alternative delivery system of EZL to enhance oral bioavailability and antiulcer activity.

show abstract

Enhanced synergistic antitumor efficacy with topotecan (camptothecin derivative) and curcumin analogs coadministration in novel proniosomal formulations

et al. 2022

View full text Add to dashboard Cite

Formulation Development and Evaluation of Proniosomal Powder of Candesartan

Cited by 3 publications

References 14 publications

Optimization of Aceclofenac Proniosomes by Using Different Carriers, Part 1: Development and Characterization

Optimization of Aceclofenac Proniosomes by Using Different Carriers, Part 1: Development and Characterization

Development, In-Vitro Characterization and Preclinical Evaluation of Esomeprazole-Encapsulated Proniosomal Formulation for the Enhancement of Anti-Ulcer Activity

Enhanced synergistic antitumor efficacy with topotecan (camptothecin derivative) and curcumin analogs coadministration in novel proniosomal formulations

Contact Info

Product

Resources

About